- £40.62m
- £41.55m
- £46.77m
Holding(s) in Company
Brief: Hvivo Completes Pilot hMPV Characterisation Study
hMPV challenge model update
Covid: 19 study published in Nature Communications
UK's hVIVO gains on $14.7 mln RSV contract
Brief: Hvivo Signs £11.5 Million RSV Contract
£11.5m RSV contract and notice of trading update
Holding(s) in Company
Holding(s) in Company
Presentation at Jefferies London Healthcare Conf
Long Term Incentive Plan/ PDMR Notification
Positive results from RSV human challenge trial
Launch of full suite of hLAB standalone services
Holding(s) in Company
Holding(s) in Company
Holding(s) in Company
Brief: Hvivo Sees FY EBITDA Margins At Upper End Of Market Expectations
Brief: hVIVO H1 Adjusted EBITDA GBP 8.734 Mln
Interim results